Cabozantinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2115 publications

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open
Published: April 15, 2026

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

Journal: Expert review of anticancer therapy
Published: April 08, 2026

The Landscape of Clinical Trials for Targeting c-MET Therapy.

The Landscape of Clinical Trials for Targeting c-MET Therapy.

Journal: American journal of clinical oncology
Published: March 30, 2026

Predicting targeted- and immunotherapeutic response outcomes in melanoma with single-cell Raman spectroscopy and AI.

Predicting targeted- and immunotherapeutic response outcomes in melanoma with single-cell Raman spectroscopy and AI.

Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026

HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.

HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.

Journal: Cancer discovery
Published: March 10, 2026

Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.

Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 03, 2026

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Journal: Journal of clinical medicine
Published: March 01, 2026

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2026

The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity.

The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 16, 2026

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026

Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).

Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).

Journal: The oncologist
Published: January 27, 2026

Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma.

Therapeutic sequencing and role of cabozantinib after immunotherapy in metastatic renal cell carcinoma.

Journal: Critical reviews in oncology/hematology
Published: January 21, 2026
Showing 1-12 of 2,115

Last Updated: 04/28/2026